

# Vascular Remodeling & Hypertension

Rok Humar, PhD  
Vascular Biology Laboratory  
Department of Research



# Structural changes in

Large arteries

Small arteries /arterioles

1.


Capillaries

2.

# Resistance vessels in blood pressure control

Resistance to blood flow/pressure is significant only in arterial vessels with a lumen diameter of  $<300 \mu\text{m}$ .

Any ***change in lumen diameter*** of these resistance vessels or ***complete loss off*** will ***affect blood pressure***.







rule of laminar flow by  
Hagen-Poiseuille:

$$R = \frac{8\eta l}{r_i^4 \pi}$$

R: resistance  
h: viscosity  
l: length of vessel  
r: lumen diameter

# Resistance vessels in blood pressure control


A small amount of arterial occlusion can have a surprisingly large effect!

Occlusion*	healthy artery	If pressure is 120 mmHg, Flowrate =	Pressure to restore normal Flowrate:
0%		100 cm <sup>3</sup> /min	120 mmHg
20%		41 cm <sup>3</sup> /min	293 mmHg
50%		6.3 cm <sup>3</sup> /min	1920 mmHg
80%		0.16 cm <sup>3</sup> /min	75,000 mmHg


\*20% occlusion here is taken to mean a reduction of the inside radius by 20%, to 80% of its original radius.

**A 19% decrease in radius will halve the volume flowrate!**

# Resistance vessels in blood pressure control



# Resistance vessels in blood pressure control




## resistance vessels

: arteries <300  $\mu\text{m}$  in diameter

: capillaries <100 $\mu\text{m}$  in diameter

# Vessel structure: capillary to artery



## **Capillary**

Endothelial cell tube

Pericytes

Basal lamina

## **Arteriole**

Endothelial cell tube

Internal elastica lamina

Smooth muscle cells

Basal lamina

External elastic lamina

## **Artery**

Endothelial cell tube -> intima

Internal elastica lamina

Smooth muscle cells -> media



Basal lamina

Fibroblasts -> adventita

Extracellular matrix

External elastica lamina








# Types of resistance artery remodeling

according Michael J. Mulvany




# Determinants of resistance artery remodeling

according Michael J. Mulvany

## Eutrophic inward Remodeling

Vasoconstrictors  
(Ang II  
Endothelin)



**Essential hypertension** is associated with eutrophic remodeling of the small arteries.

Increased neurohumoral activity leads to vasoconstriction and increased blood pressure.


Decrease in diameter (and resulting increase in wall thickness) ensures that the wall stress remains normal, thus eliminating a hypertrophic response.

**Active vasoconstriction (during essential hypertension) changes to a passive remodeling.**

# Determinants of resistance artery remodeling

*according Michael J. Mulvany*

## Hypertrophic inward Remodeling




Intravascular **pressure** causes an increase in the wall stress, which then stimulates a hypertrophic process leading to an increase in wall thickness

Increases in **flow** lead to increases in diameter and in wall thickness


Hypertrophic processes are also thought to be initiated through **growth factors**, including angiotensin II (Ang II), or PDGF

Laplace relation: wall tension = pressure x radius


# Mechanism of remodeling



# Antihypertensive treatment -> reversal of resistance vessel remodeling



# Mechanism of remodeling



# Effectors of Remodeling

## Smooth Muscle Cell Phenotype

Expression of extracellular matrix proteins and their cellular receptors is closely related to smooth muscle cell phenotype.

### Normal

contractile phenotype  
differentiated phenotype

### Tissue injury -

synthetic  
enhanced expression of extracellular matrix  
High motility and proliferation, hypertrophy

Induction of the IGF/PI 3-K keeps SMC in a differentiated state

EC-cell layer (producing IGF) important to keep SMC in differentiated state  
endothelial denudation



# Rho proteins and SMC phenotype



Phenotypic modulation of smooth muscle cells (SMC) involves dramatic changes in **expression and organization of contractile and cytoskeletal proteins**

Changes in **RhoA and Rho kinase** gene expression are required for a transition of vSMC from a stable to a dynamic, remodeling-prone state.

***contractile, differentiated***




***synthetic, proliferative***




# Rho proteins and resistance artery remodeling

Rho protein signaling is involved in excessive ***vSMC migration and proliferation*** in arterial diseases such as hypertension or atherosclerosis

Upstream signals: G-protein coupled agonists (**Ang II**, PDGF, stretch)




# SMC phenotype; contractile



$\alpha$ -SM actin (green); vinculin (red)

# Rho proteins and resistance artery remodeling




Rho kinase blockers -> in clinical trials phase I/II




# Rho proteins and resistance artery remodeling

1. Inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo



2. Rho inhibition increases regional myocardial blood flow in ischemic hearts

# Reversal of hypertension by exercise



Training-induced,  
pressure-lowering  
effect in hypertensive rats

# Remodeling in the heart

## **Mechanical stress on the heart can lead to crucially different outcomes:**

***Exercise*** is beneficial because it causes heart muscle cells to enlarge (hypertrophy).

Recent research shows that stimulation of physiological (beneficial) hypertrophy involves several signaling pathways, including those mediated by protein kinase B (also known as Akt) and the extracellular-signal-regulated kinases 1 and 2 (ERK1/2).


***Chronic hypertension*** also causes hypertrophy, but in addition it causes an excessive increase in fibroblasts and extracellular matrix (fibrosis), death of cardiomyocytes and ultimately heart failure.

Hypertension,  $\beta$ -adrenergic stimulation and agonists such as angiotensin II (Ang II) activate not only ERK1/2 but also p38 and the Jun N-terminal kinase (JNK), leading to pathological heart remodeling.



# New microvessel formation in Left Ventricular Hypertrophy

- Left ventricular hypertrophy occurs in 62% of hypertensive patients;
- first condition of heart failure




- Mismatch of number of capillaries and cardiomyocytes:
- Limited supply of nutrients and oxygen

newly forming microvessels

VEGF is required to maintain myocardial capillary density and reductions in the vascular bed are associated with the transition from compensatory hypertrophy to failure.

# New microvessel formation in response to hypoxia



A tissue is fed and grows  
Along **blood vessels**

Increased growth leads  
to **hypoxia** and necrosis


Hypoxia induces **HIF-1 $\alpha$**   
-> upregulation of **VEGF**

Angiogenic sprouting is initiated

Nutrient and oxygen supply is  
reestablished

# Microvessel regression & Hypertension

Bevacizumab (Avastin®)  
mAB against VEGF



only side effect    **grade 3 hypertension:**  
control group      -> 0.5%  
Avastin group      -> **17.5%**


# What comes first?

Rarefaction may be by

**primary** (antedated the onset of hypertension) and a result of impaired angiogenesis

or



**secondary** (occurs as a consequence of prolonged elevation of blood pressure) associated with impaired recruitment of non-perfused capillaries or destruction of capillaries



Are these processes primary **causative** events or secondary **adaptive** phenomena?


# Hypertension increases Apoptosis in Endothelial Cells from Capillaries

Kobayashi N. et al, Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2114-21.



# Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension

Antonios et al., Heart, 2003 Feb;89(2):175-8.



# Capillary rarefaction in hypertension

**Likely**, capillary rarefaction is **primary**

since

Capillary rarefaction is found before the onset of hypertension

- in experimental rat models
- in humans with mild intermittent hypertension

AND

- Capillary rarefaction is associated with familial predisposition to essential hypertension: Offspring of parents with hypertension have fewer capillaries in the dorsum of their fingers before the onset of any significant hypertension


**THUS:**

Capillary rarefaction may be genetically predetermined, and may be  
- later on- one of the reasons for the onset of hypertension.



Genetic abnormalities of capillary growth in SHR have been mapped to a region also containing growth hormones and elements of the RAAS.



# Antihypertensive treatment -> improvement of angiogenesis



# ACE inhibition -> improvement of angiogenesis



Proangiogenic Effect of Angiotensin-Converting Enzyme Inhibition (by **perindopril**) Is Mediated by the Bradykinin B2 Receptor Pathway

Silvestre et al.  
Circ Res. 2001 Oct 12;89(8):678-83.

# Keypoints

- Blood vessels undergo structural changes i.e. microvascular rarefaction and vascular remodeling
- This is an adaptive process to changes in blood pressure
- Process can be malregulated and aggravates hypertension:
- **Small resistance vessel remodeling** contributes to hypertension by a decrease in luminal diameter through eutrophic or hypertrophic inward remodeling
- **Reduction of microvessel density by microvascular rarefaction** contributes to hypertension by decrease of total arteriolar and capillary cross-sectional area.